Incidence of bleeding complications associated with Abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty

Authors
Sundlof, DW Rerkpattanapitat, P Wongpraparut, N Pathi, P Kotler, MN Jacobs, LE Ledley, GS Yazdanfar, S
Citation
Dw. Sundlof et al., Incidence of bleeding complications associated with Abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty, AM J CARD, 83(11), 1999, pp. 1569
Citations number
11
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Journal title
AMERICAN JOURNAL OF CARDIOLOGY
ISSN journal
00029149 → ACNP
Volume
83
Issue
11
Year of publication
1999
Database
ISI
SICI code
0002-9149(19990601)83:11<1569:IOBCAW>2.0.ZU;2-L
Abstract
The use of abciximab after full-dose failed thrombolytics within 15 hours o f acute myocardial infarction significantly increases the risk of major ble eding complications.